The Food and Drug Administration last week authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease. 

The combination therapy is currently authorized for use only in states and territories having 5% or fewer variants resistant to bamlanivimab and etesevimab administered together.

FDA last month authorized using the monoclonal antibody therapy REGEN-COV to prevent COVID-19 in such patients. 
 

Related News Articles

Headline
A Food and Drug Administration advisory committee today voted to recommend an emergency use authorization of Pfizer’s COVID-19 vaccine for children age 5-11.…
Headline
In a study comparing 6.4 million COVID-19 vaccine recipients with 4.6 million demographically similar unvaccinated persons, recipients of the Pfizer, Moderna…
Headline
The Equal Employment Opportunity Commission today posted updated and expanded technical assistance related to the COVID-19 pandemic, addressing questions…
Headline
Moderna today released topline results from its ongoing phase 2/3 clinical trial of its COVID-19 vaccine for children age 6 through 11, revealing a strong…
Headline
The Centers for Medicare & Medicaid Services Friday released Medicare Part B billing codes and payment allowances for reporting and administering…
Headline
The AHA today sent a letter of support for the Student Assisted Vaccination Effort (SAVE) Act (S. 2114 ), a Senate bill that would expand the types…